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Abstract
Environmental and genetic activation of a brain-adipocyte axis inhibits cancer progression. Leptin is the primary peripheral
mediator of this anticancer effect in a mouse model of melanoma. In this study we assessed the effect of a leptin receptor
antagonist on melanoma progression. Local administration of a neutralizing nanobody targeting the leptin receptor at low
dose adjacent to tumor decreased tumor mass with no effects on body weight or food intake. In contrast, systemic
administration of the nanobody failed to suppress tumor growth. Daily intraperitoneal injection of high-dose nanobody led
to weight gain, hyperphagia, increased adiposity, hyperleptinemia, and hyperinsulinemia, and central effects mimicking
leptin deficiency. The blockade of central actions of leptin by systemic delivery of nanobody may compromise its anticancer
effect, underscoring the need to develop peripherally acting leptin antagonists coupled with efficient cancer-targeting
delivery.
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Introduction
We recently report that living in an enriched housing
environment that provides physical, social, and cognitive stimuli
reduces tumor growth and increases remission in mouse models of
melanoma and colon cancer [1]. Our mechanistic studies have
elucidated one key mechanism underlying the anti-cancer effect of
environmental enrichment (EE): the activation of a previously
poorly understood neuroendocrine hypothalamic-sympatho-
neural-adipocyte axis (HSA). The complex environmental stimuli
induce the expression of brain-derived neurotrophic factor
(BDNF) in the hypothalamus and the ensuing increase in
sympathetic tone to white adipose tissue. The preferential
sympathetic activation of white adipose tissue suppresses leptin
expression and release via action on b-adrenergic receptors
leading to a robust drop of leptin level in circulation. Our
pharmacological and genetic studies demonstrate that leptin is the
key peripheral effector in the HSA axis mediating the anti-cancer
effect of EE [1]. We have developed a molecular therapy to treat
both obesity and cancer by neurosurgical delivering a recombinant
adeno-associated virus (rAAV) vector in order to overexpress
BDNF in the hypothalamus. This gene therapy reproduces the
anti-obesity and anti-cancer effects of EE [1,2]. In this study we
investigated the effect of pharmacological blockade of leptin in the
same mouse model of melanoma.
Leptin (encoded by Ob gene) is a pleotropic hormone primarily
produced in adipose tissue. Leptin plays a crucial role in energy
homeostasis by acting in the central nervous system (CNS) to
increase energy expenditure and decrease feeding via a host of
autonomic and neuroendocrine processes [3,4]. In addition to its
central effects in the CNS, leptin exhibits a large number of
peripheral actions including modulation of immune system [5,6],
regulation of liver and muscle lipid oxidation and glucose
metabolism [7–9], and regulation of pancreatic b-cell function
[10–13]. Leptin mediates its effects upon binding and activation of
the leptin receptor (LepR) encoded by the Db gene [14]. Six LepR
isoforms have been characterized: a long form (LepRb or LepRlo),
four short forms (LepRa, c, d, and f), and a soluble form (LepRe or
sLepR) [15]. The long form LepRb is considered to possess full
signaling capacity [16]. All isoforms have an identical extracellular
domain consisting of two CRH (cytokine receptor homology)
domains, CRH1 and CRH2, both separated by an immunoglob-
ulin-like domain, and followed by two additional membrane-
proximal fibronectin type III domains. To investigate the potential
of leptin antagonists in cancer treatment, choosing a neutralizing
antibody targeting the LepR instead of leptin could restrict leptin
blockade to the periphery because the antibody most likely does
not cross the blood-brain barrier (BBB). Zabeau et al generated
neutralizing nanobodies targeting LepR [17]. A nanobody
comprises the variable domain of the naturally occurring single-
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chain antibodies found in members of the Camelidae family [18].
The cloned variable domain is a stable polypeptide harboring the
full antigen-binding capacity of the original heavy-chain antibody
[19,20]. The advantages of nanobodies compared to classical
antibodies include improved tissue penetration, stability, easier
genetic manipulation and production in bacteria. Nanobody 2.17
directly against the CRH2 domain of LepR blocks leptin binding
to the receptor. To improve in vivo use, the nanobody targeting
LepR was converted into a bi-specific format by fusing it to a
nanobody that targets mouse serum albumin (mAlb). Binding to
endogenous serum albumin greatly prolonged half-life of the bi-
specific nanobody in the circulation [17]. Here we assessed the
effects of the bi-specific nanobody 2.17-mAlb in the highly
aggressive B16 melanoma model.
Materials and Methods
Mice
Male C57BL/6J mice, 6 weeks of age, were purchased from
Charles River. All protocols were approved by the Institutional
Animal Ethics Committees of the Ohio State University and were
in accordance with NIH guidelines.
Bispecific nanobody
The construction, production, and purification of bi-specific
nanobody 2.17-mAlb were described in detail before [17].
Melanoma implantation and nanobody treatment
We single housed mice for melanoma implantation and
treatment of 2.17-mAlb. In local administration experiment, mice
were shaved at the right flank. A syngeneic melanoma cell line B16
(ATCC) was subcutaneously implanted on the right flank (16105
cells per mouse). 2.17-mAlb (10 mg per mouse per injection), or
PBS as a control, was injected subcutaneously adjacent to the
tumor cell implantation site at day 1, 7, and 14 after tumor cell
implantation. We measured the size of tumor using a caliber and
calculated the tumor volume by the formula for ellipsoid
(V= length6width26p/6). Mice were sacrificed 18 days after
tumor implantation. In systemic administration experiment, B16
cells were implanted to the right flank of mice as described above.
The mice were randomized to three groups: PBS, low-dose 2.17-
mAlb, and high-dose 2.17-mAlb. 2.17-mAlb or PBS was injected
intraperitoneally immediately following tumor cell implantation
(100 mg per mouse per injection). Low-dose 2.17-mAlb mice
received 2.17-mAlb twice weekly. High-dose 2.17-mAlb mice
received daily injection. Mice were sacrificed 16 days after tumor
cell implantation. We dissected out the tumors from neighboring
tissues and measured the weight at the time of sacrifice. In the
established tumor model experiment, B16 cells were implanted to
the right flank of mice as described above. On day 5 after tumor
cell implantation when tumors became palpable, the mice were
randomized to four groups: PBS, three doses of 2.17-mAlb
treatment: 10 mg, 50 mg, and 100 mg per mouse per injection. The
mice received PBS or 2.17-mAlb injections subcutaneously
adjacent to the tumor implantation site on day 5, day 8, day 12
and day 15. Mice were sacrificed day 18 after tumor cell
implantation.
Body weight and food consumption
We maintained the mice on a normal 12 h/12 h light/dark
cycle with food and water ad libitum throughout the experiment.
Body weight of individual mouse was recorded twice weekly. Food
consumption was recorded twice weekly as the total food
consumption and represented as the average of food consumption
per mouse per day.
Serum harvest and biomarkers measurement
Blood was collected following decapitation. We prepared serum
by allowing the blood to clot for 30 min on ice followed by
centrifugation. Serum was at least diluted 1:5 in serum assay
diluent and assayed using DuoSet ELISA Development System
(R&D Systems) for mouse leptin, adiponectin, IGF-1, and soluble
leptinR. Insulin was measured using Mercodia ultrasensitive
mouse insulin ELISA (ALPCO Diagnostic). Glucose was mea-
sured using QuantiChrom Glucose Assay (BioAssay Systems).
Hypothalamic dissection
Brains were quickly isolated on ice. The hypothalamus was
dissected from 2 mm-thick-coronal sections (20.7,22.7 mm
Figure 1. Systemic effects of local administration of 2.17-mAlb
adjacent to tumor implantation site. (A) Body weight (PBS: n = 17,
2.17-mAlb: n = 23). (B) Food intake (PBS: n = 17, 2.17-mAlb: n = 23). (C)
Biomarkers in serum 18 days after 3 injections of 2.17-mAlb (total dose
30 mg per mouse). n = 10 per group, * P,0.05. Data are means6SD.
doi:10.1371/journal.pone.0089895.g001
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from bregma, 1.5 mm dorsal to the bottom of the brain, 1 mm
bilateral to the midline) under a dissection scope and stored at
280uC for further analysis.
Quantitative RT-PCR
We dissected epididymal adipose tissues and isolated total RNA
using RNeasy Lipid Kit plus RNase-free DNase treatment (Qiagen).
Tumor RNA and hypothalamic RNA were isolated using RNeasy
mini kit plus RNase-free DNase treatment. We generated first-
strand cDNA using TaqMan Reverse Transcription Reagent
(Applied Biosystems) and carried out quantitative PCR using Light
Cycler (Roche) with the Power SYBR Green PCR Master Mix
(Applied Biosystems). We designed primers to detect the following
mouse mRNAs: Agrp, Cartp, Npy, Mc4r, Pomc, Insr, Leprb, Lep, Adipoq,
Ap2, Fasn, Cpt1a, Cd31, Vegf, Kdr, Mitf, Tyrp2, and Magea4. Primer
sequences are available on request. We calibrated data to
endogenous control Actb or Hprt1 and quantified the relative gene
expression using the equation T0/R0=K62
(CT,R-CT,T). T0 is the
initial number of target gene mRNA copies, R0 is the initial number
of internal control gene mRNA copies, CT,T is the threshold cycle
of the target gene, CT,R is the threshold cycle of the internal control
gene and K is a constant.
Cell proliferation
We cultured B16 melanoma cells (5000 cells/well in 96-well
plate) with DMEM medium plus 1% mouse serum with or without
2.17-mAlb (50 mg/ml) for 3 days. Proliferation was measured
using the CellTiter 96Aquesous One Solution Cell Proliferation
Assay (Promega).
Western blot
The dissected tumors were lysed in 100 ml RIPA buffer
containing 1% proteinase inhibitor (Calbiochem 539134) by
sonication. Rabbit Anti-CD31 (Abcam ab28367, 1:300), rabbit
Anti-VEGF (Abcam ab46154, 1:1000), mouse Anti-GAPDH
(Calbiochem CB1001, 1:1000) were used in western blot analysis.
Statistical analysis
Values are expressed as mean 6 SD. We used JMP software to
analyze the following: repeated measures MANOVA for food
intake, weight gain, and tumor volume; one-way ANOVA for
serum biomarker measurements, tumor weight and adipose tissue
weight, quantitative RT-PCR data, western blot quantification.
Figure 2. Local administration of 2.17-mAlb inhibited melano-
ma progression. (A) Tumor volume (P,0.05. PBS: n = 17, 2.17-mAlb:
n = 23). (B) Tumor weight (PBS: n = 17, 2.17-mAlb: n = 23. * P,0.05). (C)
2.17-mAlb inhibited B16 melanoma growth in vitro when cultured with
mouse serum (n= 4. * P,0.05). Data are means6SD.
doi:10.1371/journal.pone.0089895.g002
Figure 3. Local administration of low dose 2.17-mAlb modu-
lated gene expression in melanoma. (A) Gene expression in tumor
(n = 5 per group. * P,0.05). Mitf, microphthalmia-associated transcrip-
tion factor; Tyrp2, tyrosinase related protein 2; Magea4, melanoma
antigen family A4. Data are means6SD. (B) Western blot of tumors.
doi:10.1371/journal.pone.0089895.g003
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Results
Local administration of a nanobody targeting LepR
We firstly assessed the effect of nanobody 2.17-mAlb on
melanoma progression when injected adjacent to the tumor
implantation site. B16 melanoma cells were injected subcutane-
ously to the flank of male C57BL/6J mice. One day after tumor
cell implantation, a low-dose of nanobody 2.17-mAlb (10 mg/
mouse) or PBS was injected subcutaneously adjacent to the tumor
cell implantation site. The nanobody or PBS control was injected
at day 7 and day 14 at the same dose and the experiment was
terminated at day 18 after tumor cell implantation. The nanobody
2.17-mAlb treatment did not affect weight gain (Fig. 1A) or food
intake (Fig. 1B) indicating the absence of central effects. We
observed a signature biomarker change in the serum associated
with EE-induced inhibition of melanoma including decreased
leptin, increased adiponectin, and decreased IGF-1 [1]. The
subcutaneous administration of low-dose 2.17-mAlb had no
significant effects on circulating leptin, adiponectin, or IGF-1
(Fig. 1C). Leptin inhibits insulin expression and secretion and
affects b-cell mass [21]. The low-dose 2.17-mAlb had no
significant effect on serum insulin while decreased blood glucose
levels were observed (Fig. 1C). Interestingly, 2.17-mAlb signifi-
cantly increased sLepR level in the circulation (Fig. 1C). Local
administration of low-dose 2.17-mAlb (30 mg/mouse the whole
course) significantly slowed the melanoma growth (Fig. 2A) and
decreased melanoma mass by 33.167.9% (Fig. 2B). Quantitative
RT-PCR was used to measure relative expression levels of
transcription factors and antigens which have been associated
with melanocyte differentiation and progression including mi-
crophthalmia-associated transcription factor (Mitf), silver gp100,
tyrosinase, tyrosinase related protein 1, and 2 (Tyrp), as well as
melanoma antigen family A2 and A4 (Mage). MITF, the
transcription factor regulating the development and differentiation
of melanocytes [22] was significantly elevated in 2.17-mAlb
treated mice, as was TYRP-2 (Fig. 3A). MITF leads to
differentiation, pigmentation and cell-cycle arrest in melanocytes.
Progression of melanoma is associated with decreased differenti-
ation and lower expression of MITF although its function may not
be the same in melanoma as in normal melanocytes [23]. The
increase in MITF and the genes in its pathway found in 2.17-mAlb
treated animals may indicate more differentiated and less
progressive tumor. Similar molecular changes were found in EE-
induced inhibition of melanoma progression including increased
Mitf, Maega4 and Tyrp2 (Data not shown). Leptin plays a role in
modulating angiogenesis. 2.17-mAlb decreased the expression of
vascular marker CD31 and the key VEGF receptor KDR that is
critical to tumor angiogenesis (Fig. 3A) suggesting that the
nanobody suppressed angiogenesis. Western blot showed that
the VEGF protein level was significantly reduced by 60.3612.7%
Figure 4. Intraperitoneal administration of 2.17-mAlb. (A) High-dose intraperitoneal administration of 2.17-mAlb accelerated weight gain
(n = 10 per group, P,0.05 high-dose 2.17-mAlb compared to PBS and low-dose 2.17-mAlb. No significance between low-dose 2.17-mAlb and PBS). (B)
High-dose 2.17-mAlb increased food intake (n = 10 per group, P,0.05 high-dose 2.17-mAlb compared to PBS and low-dose 2.17-mAlb. No
significance between low-dose 2.17-mAlb and PBS). (C) Biomarkers in serum (n= 10 per group. Bars not connected by same letter are significantly
different. (D) Tumor weight (n = 10 per group). Data are means6SD.
doi:10.1371/journal.pone.0089895.g004
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(P=0.042) (Fig. 3B). In an in vitro experiment, the expression of
LepR in B16 melanoma cells was confirmed by RT-PCR. In a cell
proliferation experiment, B16 melanoma cells were cultured with
mouse serum. 2.17-mAlb substantially attenuated the effect of
mouse serum on tumor cell proliferation (Fig. 2C). These results
showed that the nanobody targeting LepR efficiently inhibited
melanoma proliferation in vitro and tumor progression in vivo
possibly via direct effect on cancer cell proliferation and indirect
effects on tumor angiogenesis.
Systemic administration of nanobody targeting LepR
We next evaluated the effects of nanobody when administrated
systemically. The B16 melanoma cells were implanted to the flank
of mice and the 2.17-mAlb was injected intraperitoneally (i.p.
100 mg/mouse) immediately following the tumor cell implanta-
tion. In the low-dose group, nanobody was injected twice weekly (5
injections in total). In the high-dose group, nanobody was injected
daily till the end of the experiment at day 16. Intraperitoneal
administration of nanobody showed dose-dependent effects on
weight gain and food intake. High-dose nanobody led to
accelerated weight gain (Fig. 4A) and hyperphagia (Fig. 4B) while
low-dose nanobody showed no significant changes. In contrast to
local administration, intraperitoneal administration of nanobody
failed to inhibit melanoma growth (Fig. 4D). High-dose nanobody
markedly increased the adiposity with visceral fat pad increased by
51.366.6% (Fig. 5A). Consistent with the increased fat mass,
serum leptin level was increased in the high-dose group while
adiponectin and IGF-1 were not affected (Fig. 4C). Insulin level
was significantly increased in the high-dose group (Fig. 4C). The
hyperleptinemia and hyperinsulinemia could compromise the anti-
cancer effect of 2.17-mAlb. The sLepR level was substantially
increased in both low-dose and high-dose 2.17-mAlb treated mice
(Fig. 4C). The increase of sLepR was dose-dependent with high-
dose i.p. 2.17-mAlb showing the largest increase while low-dose
2.17-mAlb injected locally showing the smallest change (Fig. 4C,
Fig. 1C). We examined the gene expression of visceral fat by
quantitative RT-PCR. High-dose 2.17-mAlb increased leptin
expression in the adipose tissue (Fig. 5B). Ap2, an adipocyte
differentiation marker was also increased consistent with the
expansion of fat depot [24]. Leprb, the long-form leptin receptor,
showed a trend of increase (Fig. 5B) probably indicating an
adaptive response to the antagonism to LepR. The accelerated
weight gain and hyperphagia suggested that high-dose intraper-
itoneal administration of 2.17-mAlb antagonized central actions of
leptin. Leptin acts on two populations of neurons in the arcuate
nucleus of hypothalamus, with one population expressing Pro-
opiomelanocortin (POMC), the other co-expressing neuropeptide
Y (NPY) and agouti-related peptide (AgRP) [25,26]. We profiled
gene expression in the hypothalamus by quantitative RT-PCR
(Fig. 6). The orexigenic neuropeptides NPY and AgRP were
significantly induced consistent with the increase in food intake.
The anorexigenic POMC and CART prepropeptide (Cartpt) as
well as the melanocortin 4 receptor (MC4R), a key pathway
regulating energy balance [27], were not affected (Fig. 6).
Nanobody targeting LepR in established tumor model
We next tested the efficacy of nanobody targeting LepR in the
established melanoma model. The B16 cells were implanted to the
flank of the mice. Local subcutaneous nanobody treatment was
delayed to day 5 after tumor cells implantation when tumors
became palpable. Three dose levels (10 mg, 50 mg, and 100 mg per
mouse per injection) were used. Low dose nanobody (10 mg per
injection, 40 mg the whole course) had no effects on weight gain
(Fig. 7A), food intake (Fig. 7B), or adiposity (Fig. 7C). Low dose
nanobody significantly decreased tumor mass even with shorter
window of treatment (Fig. 7D). In contrast, subcutaneous injection
of high dose nanobody failed to inhibit tumor growth (Fig. 7D).
High dose nanobody treatment (s.c. 100 mg per injection, 400 mg
the whole course) led to accelerated weight gain (Fig. 7A),
increased food intake (Fig. 7B), increased fat pad mass (Fig. 7C),
elevated leptin and insulin levels in the circulation (Fig. 7E). These
Figure 5. Intraperitoneal administration of high-dose 2.17-
mAlb increased adiposity. (A) Subcutaneous and visceral fat pad
weight (n = 10 per group. * P,0.05). (B) Gene expression profile of
epididymal fat (n = 5 per group. * P,0.05, + P= 0.08). Data are
means6SD.
doi:10.1371/journal.pone.0089895.g005
Figure 6. Intraperitoneal administration of high-dose 2.17-
mAlb affected hypothalamic gene expression. n= 5 per group.
* P,0.05. Data are means6SD.
doi:10.1371/journal.pone.0089895.g006
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changes were similar to the intraperitoneal administration of high
dose nanobody (daily i.p. 100 mg per injection) although to a
smaller degree (Fig. 4).
Discussion
Leptin is not only the metabolic switch that conveys metabolic
information to the brain but is also involved in multiple pathways
affecting many peripheral organs as a mitogen, metabolic
regulator, survival or angiogenic factor depending on the tissue
type [28]. Clinical reports link elevated serum leptin levels to an
increased risk of certain cancers including prostate [29], breast
[30], and melanoma [31]. In vitro and preclinical in vivo data
suggest that leptin acts as a mitogenic agent to promote prostate,
breast, and ovarian cancer cell growth and/or enhances cancer
angiogenesis and migration [32–34]. Thus leptin antagonists hold
potential for future therapeutic use in cancer. A few anti-LepR
antibodies have been generated and tested in models of heart
failure [35], multiple sclerosis [36], and autoimmune encephalo-
myelitis [37]. An anti-rat LepR mAb reduced the growth of bone
marrow leukemic cells with concomitant decrease in angiogenesis,
and prolonged survival [38]. A pegylated leptin peptide antagonist
(LPA) significantly inhibited breast cancer xenografts hosted by
immunodeficient mice without affecting energy balance [39].
Figure 7. Subcutaneous administration of 2.17-mAlb in the established tumor model when treatment was delayed till palpable
tumors appeared. (A) Weight gain (n = 9 per group, P,0.05 2.17-mAlb 100 mg compared to PBS and 2.17-mAlb 10 mg. No significance between
other groups). (B) Food intake (n = 9 per group, P,0.05 2.17-mAlb 100 mg compared to PBS and 2.17-mAlb 10 mg. No significance between other
groups). (C) Epididymal fat pad weight (n = 9 per group, bars not connected by same letter are significantly different). (D) Tumor weight (n = 9 per
group, bars not connected by same letter are significantly different). (E) Biomarkers in serum (n= 9 per group, bars not connected by same letter are
significantly different). Data are means6SD.
doi:10.1371/journal.pone.0089895.g007
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In this study we assessed the effects of a neutralizing anti-LepR
nanobody in a mouse model of melanoma. Local subcutaneous
administration of low-dose 2.17-mAlb significantly inhibited
melanoma growth associated with decreased angiogenesis in the
tumor. The absence of effects on weight and food intake suggested
that the central actions of leptin were not disrupted by low-dose
2.17-mAlb although the low-dose nanobody administered adjacent
to the tumor was sufficient to decrease the growth of a highly
aggressive melanoma by 33%. These results further support our
finding that the EE-induced anti-cancer effect was mediated, at
least in part, by leptin.
The effects of high dose 2.17-mAlb are more complex. The
intraperitoneal injection of 2.17-mAlb at high-dose (100 mg/
mouse, daily) resulted in weight gain, hyperphagia, increased
adiposity, hyperleptinemia, and hyperinsulinemia indicating effi-
cient blockade of leptin signaling in CNS. On the other hand, low-
dose 2.17-mAlb (i.p. 100 mg/mouse, twice weekly, 500 mg the
whole course) showed neither significant metabolic effects nor anti-
cancer effect suggesting that the antagonist availability and activity
were insufficient at the respective sites of action. Therefore the
overall impact of 2.17-mAlb on tumor growth was determined not
only by the direct effects of LepR antagonist on tumor cells and/or
other cells supporting tumor growth, but also by other systemic
factors such as insulin metabolism that are regulated by leptin. In
the context of cancer, insulin signaling and thus the role of leptin
in the regulation of pancreatic b-cell functions are of importance.
Our previous data have shown that obesity increases B16
melanoma growth in obese leptin-deficient ob/ob mice consistent
with other reports [1,40]. Prevention of the obesity by pair feeding
ob/ob mice dramatically reduces tumor weight to a level
significantly lower than wild-type mice of the same weight [40].
Our leptin replacement data also showed that exogenous leptin
increased melanoma mass in ob/ob mice by 140% compared to
pair-fed saline-infused mice with identical body weight and fat
mass [1]. These data all support the role of leptin in promoting
melanoma growth. The hyperinsulinemia associated with leptin
deficiency in ob/ob mice may underlie the accelerated tumor
growth in ob/ob mice and similarly could counteract the anti-
cancer effect of 2.17-mAlb in the high-dose administration
experiment. Although leptin modulates glucose metabolism via
central and peripheral mechanisms, the pancreatic b-cells is a
critical target of leptin actions [21]. LepRs are expressed in the b-
cells and their activation directly inhibits insulin secretion. Long-
term leptin deficiency inhibits insulin gene expression and b-cells
mass [21]. Therefore the adverse effects on b-cells and insulin
require attention for the development and application of leptin
antagonists.
High dose nanobody targeting LepR blocked leptin signaling in
the hypothalamus as evidenced by induction of orexigenic NPY
and AgRP as well as hyperphagia and increased adiposity. There
is little evidence from the literature that nanobodies are actively or
passively transported across BBB [17]. The only two nanobodies
known to transmigrate in an in vitro human BBB model and in vivo
were generated by enrichment of a phage-display nanobody
library with human cerebromicrovascular endothelial cells [41].
One explanation might be that the leptin-sensing neurons in the
arcuate nucleus could make direct contact with the blood
circulation [42–44]. Another idea is that the nanobodies targeting
LepR could disrupt the transportation of leptin across BBB. In this
study, we observed a robust increase of sLepR in 2.17-mAlb
treated mice even when low-dose of nanobody was used. sLepR
deriving from shedding of the extracellular domain is the main
binding protein for leptin in the blood and modulates the
bioavailability of leptin [15,45,46]. Experimental and clinical
studies demonstrate an important role of sLepR as modulator of
leptin action [47–50]. The regulatory mechanisms for the
generation of sLepR are not well understood. A recent report
suggests that lipotoxicity and apoptosis increase LepR cleavage via
ADAM10 (A Disintegrin and Metalloproteinase 10) as a major
protease [51]. sLepR mainly originates from short LepR isoforms
[51,52]. Leptin transport across BBB is thought to be dependent
on short LepR isoforms [53–55]. The increase in sLepR could
indicate elevated shedding of short LepR isoforms and therefore
could restrain leptin transport and subsequently impair central
action of leptin [56]. An alternative explanation for the increase of
sLepR level in nanobody-treated mice could be that the sLepR is
bound by 2.17-mAlb and thereby is retained from clearance from
circulation. Therefore more research is needed to understand the
regulatory mechanisms of the expression of LepR isoforms and the
constitutive shedding of the extracellular domain as well as the
roles of these isoforms in controlling leptin transport, bioavailabil-
ity, and binding and activating signaling pathways in order to
design LepR antagonists as potential therapeutics. The idea that
large molecules such as nanobodies or antibodies cannot cross the
BBB and therefore can restrict their actions to the periphery seems
overly simplistic. Our data raise several questions in targeting
leptin signaling as a treatment for cancer: how to restrict
antagonizing actions to the periphery; how to prevent adverse
effects such as hyperinsulinemia; how to improve bioavailability to
cancer. Coupling the nanobody to the agents specifically targeting
the tumor (antibody or drug conjugates) [57] may enhance the
anti-cancer efficacy while prevent adverse peripheral and central
effects of leptin deficiency.
In summary, we demonstrated the anti-cancer effect of a
neutralizing nanobody targeting LepR in a mouse model of
melanoma. Systemic administration of high dose nanobody led to
blockade of central actions of leptin and may compromise the anti-
cancer effect of the nanobody. These data provide insights for
development of LepR antagonists as treatment for cancer.
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